The nomogram developed recently by Yu et al. [2] is the only one available up to date for the new JM-103 bilirubinometer. We conducted a small study to compare the accuracy and capability to predict significant hyperbilirubinemia of two new multiwavelength transcutaneous bilirubinometers as part of a quality improvement project that pretends to introduce one of these devices in a community-based hospital. Seventy-one full-term newborns were included in this study and were performed three different measurements: TSB via heel stick, TcB level with Minolta JM-103, and TcB level with Respironics BiliCheck. The levels of bilirubin were categorized according to the risk zones of hyperbilirubinemia, as either low-risk zone, intermediate-risk zone, or high-risk zone based in the JM-103 nomogram by Yu et al. and the Bilicheck nomogram published by Varvarigou et al. [1, 2] The mean total serum bilirubin was 7.56±2.48 mg/dL. The mean levels of TcB were 7.3±2.8 for JM-103 and 7.9±3.1 for BiliCheck. Both devices were strongly correlated with TSB (r=0.86 for JM-103 and r=0.85 for BiliCheck). The mean difference of serum and transcutaneous levels is −0.11±1.43 for JM-103 and for 0.42±1.61 for BiliCheck.
